Norethisterone
Brand names: Primolut N, Utovlan
Norethisterone is an orally active progestogen used in gynaecology to manage heavy or irregular menstrual bleeding, dysmenorrhoea, endometriosis and to delay menstruation.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It acts on progesterone receptors to oppose oestrogen-driven endometrial proliferation, stabilising the endometrium and, at higher exposure, suppressing the hypothalamic-pituitary-ovarian axis.
Prescribing in practice
- Although a progestogen, norethisterone is partly metabolised to ethinylestradiol, so it carries a venous thromboembolism risk and should be used with caution in women with thrombotic risk factors.
- It is contraindicated in undiagnosed vaginal bleeding and active venous thromboembolism, and bleeding may occur when treatment stops.
- It is not a reliable contraceptive at doses used for menstrual control and must not be relied upon for that purpose.
Monitoring
Assess bleeding pattern and symptom response, and review cardiovascular and thrombotic risk factors before and during use.
Counselling the patient
- This does not provide reliable contraception at the doses used for period control.
- A withdrawal bleed is expected a few days after stopping a short course to delay periods.
- Seek urgent advice for calf swelling or pain, chest pain or breathlessness.
Evidence & guidelines
Norethisterone is an established progestogen option in NICE guidance for heavy menstrual bleeding and related gynaecological indications.
Reference: NICE NG88 (Heavy Menstrual Bleeding 2018); ESHRE Endometriosis Guideline (2022); SPC Primolut N; RCOG Clinical Governance Advice No. 6; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.